Navigation Links
Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company

SAN DIEGO, Oct. 21, 2011 /PRNewswire/ -- Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at KV Pharmaceutical Company (NYSE: KV-A, KV-B).


Robbins Umeda LLP's investigation focuses on whether officials at KV Pharmaceuticals breached their fiduciary duties to shareholders, maintained woefully inadequate controls, and wasted corporate assets to the detriment of the company and investors.  In particular, the firm is investigating allegations that officials at the company caused KV Pharmaceuticals to misrepresent the extent of expanded patent access granted by the U.S. Food and Drug Administration (the "FDA") for its Makena product line.  After gaining FDA approval, officials at the company made the decision to increase the price of Makena by over 1490% to $1,500.  

On March 17, 2011, two United Stated Senators sent a letter to the Federal Trade Commission stating that "KV Pharmaceuticals actions will result in diminished access to appropriate healthcare for women and result in increased preterm birth." Additionally, on March 30, 2011, the FDA issued a statement that it would not take enforcement action against companies that manufactured compound or generic versions of Makena.

Since these facts have emerged, KV Pharmaceuticals has been forced to lower the price of its Makena product line.  In addition, the company is increasingly the subject of costly public and legal scrutiny.  These events have apparently taken its toll on KV Pharmaceutical's stock price.  After recently trading as high as $13.07 per share on March 8, 2011, shares of KV Pharmaceuticals closed on October 19, 2011, at just $1.39 per share.  

If you own shares of KV Pharmaceuticals and would like more information about your rights, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or via the shareholder information form on our website.  

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more information, please go to

Press release link:

Attorney Advertising.

SOURCE Robbins Umeda LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Robbins & Myers Announces Regular Quarterly Cash Dividend
2. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
3. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
4. Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Robbins & Myers to Present at KeyBanc Capital Markets Conference
7. Robbins & Myers to Present at Bairds 2010 Industrial Conference November 9, 2010
8. Robbins Geller Rudman & Dowd LLP Announces Notice of Hearing to Determine Approval of Proposed Settlement of Class Action
9. Robbins & Myers to Release Financial Results for Second Quarter Fiscal 2011
10. Robbins & Myers Completes Sale of Romaco Businesses
11. Robbins & Myers Announces Regular Quarterly Cash Dividend
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... were," said an inventor from Hillside, N.J. "Many people catch diseases simply from ... that individuals will always be protected from germs." , He developed the patent-pending ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):